vs
EXACT SCIENCES CORP（EXAS）与亨廷顿·英格尔斯工业（HII）财务数据对比。点击上方公司名可切换其他公司
亨廷顿·英格尔斯工业的季度营收约是EXACT SCIENCES CORP的1.9倍（$1.7B vs $878.4M），亨廷顿·英格尔斯工业净利率更高（8.9% vs -9.8%，领先18.7%），EXACT SCIENCES CORP同比增速更快（23.1% vs 13.8%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-461.0M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -25.2%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
亨廷顿·英格尔斯工业（简称HII）是美国规模最大的军用造船企业，同时面向政府及行业合作伙伴提供专业服务。公司于2011年3月31日从诺斯罗普·格鲁曼公司分拆成立，在防务装备建造及配套服务领域拥有深厚技术积累与行业资源。
EXAS vs HII — 直观对比
营收规模更大
HII
是对方的1.9倍
$878.4M
营收增速更快
EXAS
高出9.3%
13.8%
净利率更高
HII
高出18.7%
-9.8%
自由现金流更多
EXAS
多$581.4M
$-461.0M
两年增速更快
EXAS
近两年复合增速
-25.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.7B |
| 净利润 | $-86.0M | $149.0M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 9.3% |
| 净利率 | -9.8% | 8.9% |
| 营收同比 | 23.1% | 13.8% |
| 净利润同比 | 90.1% | — |
| 每股收益（稀释后） | $-0.45 | $3.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASHII
| Q1 26 | — | $1.7B | ||
| Q4 25 | $878.4M | $3.5B | ||
| Q3 25 | $850.7M | $3.2B | ||
| Q2 25 | $811.1M | $3.1B | ||
| Q1 25 | $706.8M | $2.7B | ||
| Q4 24 | $713.4M | $3.0B | ||
| Q3 24 | $708.7M | $2.7B | ||
| Q2 24 | $699.3M | $3.0B |
净利润EXASHII
| Q1 26 | — | $149.0M | ||
| Q4 25 | $-86.0M | $159.0M | ||
| Q3 25 | $-19.6M | $145.0M | ||
| Q2 25 | $-1.2M | $152.0M | ||
| Q1 25 | $-101.2M | $149.0M | ||
| Q4 24 | $-864.6M | $123.0M | ||
| Q3 24 | $-38.2M | $101.0M | ||
| Q2 24 | $-15.8M | $173.0M |
毛利率EXASHII
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EXASHII
| Q1 26 | — | 9.3% | ||
| Q4 25 | -9.4% | 4.9% | ||
| Q3 25 | -3.0% | 5.0% | ||
| Q2 25 | -0.3% | 5.3% | ||
| Q1 25 | -13.6% | 5.9% | ||
| Q4 24 | -122.8% | 3.7% | ||
| Q3 24 | -5.6% | 3.0% | ||
| Q2 24 | -3.8% | 6.3% |
净利率EXASHII
| Q1 26 | — | 8.9% | ||
| Q4 25 | -9.8% | 4.6% | ||
| Q3 25 | -2.3% | 4.5% | ||
| Q2 25 | -0.1% | 4.9% | ||
| Q1 25 | -14.3% | 5.4% | ||
| Q4 24 | -121.2% | 4.1% | ||
| Q3 24 | -5.4% | 3.7% | ||
| Q2 24 | -2.3% | 5.8% |
每股收益（稀释后）EXASHII
| Q1 26 | — | $3.79 | ||
| Q4 25 | $-0.45 | $4.06 | ||
| Q3 25 | $-0.10 | $3.68 | ||
| Q2 25 | $-0.01 | $3.86 | ||
| Q1 25 | $-0.54 | $3.79 | ||
| Q4 24 | $-4.69 | $3.15 | ||
| Q3 24 | $-0.21 | $2.56 | ||
| Q2 24 | $-0.09 | $4.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $216.0M |
| 总债务越低越好 | — | $2.7B |
| 股东权益账面价值 | $2.4B | $5.1B |
| 总资产 | $5.9B | $12.5B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资EXASHII
| Q1 26 | — | $216.0M | ||
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — |
总债务EXASHII
| Q1 26 | — | $2.7B | ||
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EXASHII
| Q1 26 | — | $5.1B | ||
| Q4 25 | $2.4B | $5.1B | ||
| Q3 25 | $2.5B | $5.0B | ||
| Q2 25 | $2.5B | $4.9B | ||
| Q1 25 | $2.4B | $4.8B | ||
| Q4 24 | $2.4B | $4.7B | ||
| Q3 24 | $3.2B | $4.2B | ||
| Q2 24 | $3.2B | $4.2B |
总资产EXASHII
| Q1 26 | — | $12.5B | ||
| Q4 25 | $5.9B | $12.7B | ||
| Q3 25 | $5.9B | $12.3B | ||
| Q2 25 | $5.8B | $12.1B | ||
| Q1 25 | $5.7B | $12.1B | ||
| Q4 24 | $5.9B | $12.1B | ||
| Q3 24 | $6.7B | $11.1B | ||
| Q2 24 | $6.7B | $11.3B |
负债/权益比EXASHII
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.53× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $-390.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-461.0M |
| 自由现金流率自由现金流/营收 | 13.7% | -27.7% |
| 资本支出强度资本支出/营收 | 3.6% | 4.4% |
| 现金转化率经营现金流/净利润 | — | -2.62× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $795.0M |
8季度趋势，按日历期对齐
经营现金流EXASHII
| Q1 26 | — | $-390.0M | ||
| Q4 25 | $151.7M | $650.0M | ||
| Q3 25 | $219.9M | $118.0M | ||
| Q2 25 | $89.0M | $823.0M | ||
| Q1 25 | $30.8M | $-395.0M | ||
| Q4 24 | $47.1M | $391.0M | ||
| Q3 24 | $138.7M | $213.0M | ||
| Q2 24 | $107.1M | $-9.0M |
自由现金流EXASHII
| Q1 26 | — | $-461.0M | ||
| Q4 25 | $120.4M | $516.0M | ||
| Q3 25 | $190.0M | $13.0M | ||
| Q2 25 | $46.7M | $727.0M | ||
| Q1 25 | $-365.0K | $-462.0M | ||
| Q4 24 | $10.7M | $277.0M | ||
| Q3 24 | $112.6M | $125.0M | ||
| Q2 24 | $71.2M | $-99.0M |
自由现金流率EXASHII
| Q1 26 | — | -27.7% | ||
| Q4 25 | 13.7% | 14.8% | ||
| Q3 25 | 22.3% | 0.4% | ||
| Q2 25 | 5.8% | 23.6% | ||
| Q1 25 | -0.1% | -16.9% | ||
| Q4 24 | 1.5% | 9.2% | ||
| Q3 24 | 15.9% | 4.5% | ||
| Q2 24 | 10.2% | -3.3% |
资本支出强度EXASHII
| Q1 26 | — | 4.4% | ||
| Q4 25 | 3.6% | 3.9% | ||
| Q3 25 | 3.5% | 3.3% | ||
| Q2 25 | 5.2% | 3.1% | ||
| Q1 25 | 4.4% | 2.5% | ||
| Q4 24 | 5.1% | 3.8% | ||
| Q3 24 | 3.7% | 3.2% | ||
| Q2 24 | 5.1% | 3.0% |
现金转化率EXASHII
| Q1 26 | — | -2.62× | ||
| Q4 25 | — | 4.09× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 5.41× | ||
| Q1 25 | — | -2.65× | ||
| Q4 24 | — | 3.18× | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | -0.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
HII
暂无分部数据
